GSK Korea Head Rebuffs Speculation About Hostile Takeover Of Dong-A
This article was originally published in PharmAsia News
Executive Summary
SEOUL - GlaxoSmithKline said it is not pursuing a hostile takeover of South Korea's leading drug firm Dong-A Pharmaceutical despite market speculation triggered when the multinational company bought 9.9 percent of Dong-A's equity in May
You may also be interested in...
GSK Korea Moving Ahead To Sell Avandia With Korea's Dong-A Despite U.S. FDA Safety Study
SEOUL - Immediately following a joint U.S. FDA advisory committee vote July 14 recommending that Avandia remain on the market, GlaxoSmithKline Korea said its plan to co-market its diabetes medicine with South Korea's Dong-A Pharmaceutical will proceed as scheduled in the second half of the year
GSK Korea Moving Ahead To Sell Avandia With Korea's Dong-A Despite U.S. FDA Safety Study
SEOUL - Immediately following a joint U.S. FDA advisory committee vote July 14 recommending that Avandia remain on the market, GlaxoSmithKline Korea said its plan to co-market its diabetes medicine with South Korea's Dong-A Pharmaceutical will proceed as scheduled in the second half of the year
South Korean Pharmas Clamber For Partnerships To Survive Rapidly Changing Environment
SEOUL - South Korea's local pharmas are clambering to tie the knot with multinationals and among themselves in what appears to be a "marriage of necessity" in a desperate attempt to survive a government crackdown on rebates, on which locals have long depended